Biogen has agreed to acquire Pfizer’s PF-05251749, a Phase I asset in development for the treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD), in exchange for US$75 M upfront. The deal comes just months after Biogen’s AD therapy aducanumab was resurrected after the drug failed futility analyses in Phase III studies. Biogen plans to submit a regulatory filing for aducanumab in early 2020, which has the potential to become the first therapy to reduce the clinical decline of AD, if approved.